계명대학교 의학도서관 Repository

Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review

Metadata Downloads
Author(s)
Gaeun KimJuyoung KimYoo Li LimMoon Young KimSoon Koo Baik
Keimyung Author(s)
Kim, Ga Eun
Department
Dept. of Nursing (간호학)
Research Institute for Nursing Science (간호과학연구소)
Journal Title
Hepatology International
Issued Date
2016
Volume
10
Issue
5
Keyword
Renin–angiotensin systemHepatic fibrosisSystematic reviewMeta-analysis
Abstract
Background and aims.

The renin–angiotensin system (RAS) has an important role in hepatic fibrosis and portal hypertension. RAS inhibitors are already accepted in clinical fields for antihypertensive management, but their effects on hepatic fibrosis are controversial. The aim of this study was to systematically review the effects of RAS inhibitors on hepatic fibrosis based on histological assessment.


Methods.

We performed a systematic review and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE, and Cochrane Library databases (up to January 2015) to identify clinical studies evaluating the effects of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on hepatic fibrosis or cirrhosis patients based on histological assessment. Of the 455 studies identified, we analyzed 7, including a total of 1066 patients, which met our selection criteria.


Results.

According to the MA, patients treated with RAS inhibitors had significantly lower fibrosis scores (SMD −0.68, 95 % CI −1.03, −0.34, I 2 = 0 %, p < 0.0001) and smaller fibrosis areas (SMD −0.80, 95 % CI −1.18, −0.41, I 2 = 0 %, p < 0.0001) than controls. Serum fibrosis markers such as TGF-β1, collagen I, IV, TIMP-1, and MMP2 were significantly reduced in the intervention group. In two studies, mean arterial pressures were significantly decreased in RAS inhibitor users, but there were no reports about symptoms related to decreased blood pressure. No significant difference was found in serum creatinine levels between the intervention and control groups, and significant renal dysfunction was not observed after administration of RAS inhibitors.


Conclusions.

RAS inhibitors are potential therapeutic agents for hepatic fibrosis, which can be safely used in patients with chronic liver disease.
Keimyung Author(s)(Kor)
김가은
Publisher
College of Nursing
Citation
Gaeun Kim et al. (2016). Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatology International, 10(5), 819–828. doi: 10.1007/s12072-016-9705-x
Type
Article
ISSN
1936-0533
Source
https://link.springer.com/article/10.1007%2Fs12072-016-9705-x
DOI
10.1007/s12072-016-9705-x
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/32768
Appears in Collections:
2. College of Nursing (간호대학) > Dept. of Nursing (간호학)
3. Research Institutues (연구소) > Research Institute for Nursing Science (간호과학연구소)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.